The third novel finding of the present study is that LPL selective activator Ibrolipim, given for 5 months in combination with HSFD, significantly reduces hyperglycemia, hyperinsulinemia, insulin resistance, hypertriglyceridemia, microalbuminuria, renal fat accumulation, and improves pathological injury, all consistent with the increase in renal LPL activity and expression. This evidence concerns the gene LPL and hyperinsulinism.